Study on drug-mediated protein–protein interaction in single living cells by fluorescence cross-correlation spectroscopy
Authors:
- 8 April 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 150 (10) , 2029-2038
Abstract
Drug-mediated protein–protein interaction and drug–protein interaction form the basis of drug development and pharmacological research. How to obtain the information of drug–protein or protein–protein interaction in living cells is still a big challenge. In this work, we reported a new method for studying drug-mediated protein–protein interaction in living cells by using fluorescence cross-correlation spectroscopy (FCCS). We used the mammalian target of rapamycin (mTOR) as a model and studied drug-mediated FRB protein–FKBP12 protein interaction in living cells. The FRB protein covers amino acid residues of mTOR from 2015 to 2114 and FKBP12 is a receptor-binding protein. First, FRB was fused with the green fluorescent protein EGFP (FRB–EGFP), and FKBP12 was fused with the red fluorescent protein mCherry (FKBP12–mCherry) using genetic engineering technology. Then, FCCS was used to obtain information on drug-mediated FRB protein–FKBP12 protein interaction in living cells. According to the autocorrelation curves and cross-correlation curves, we can obtain cross-correlation (CC) values of the interaction between two proteins. The CC value was positively correlated with the interaction between two proteins. Furthermore, we developed a method for measuring IC50 for evaluating drug efficacy in living cells based on CC values. Compared with the current methods, our method can be used to study drug-mediated protein–protein interaction and evaluate effects of drugs on protein–protein interaction in living cells, and may become a useful tool for drug development and pharmacological research.Keywords
Funding Information
- National Natural Science Foundation of China (22274098)
- National Natural Science Foundation of China (22027803)
- National Natural Science Foundation of China (21834005)
- National Natural Science Foundation of China (21874090)
This publication has 50 references indexed in Scilit:
- mTOR activity paces human blastocyst stage developmental progressionCell, 2024
- Inhibitors of the mTOR signaling pathway can play an important role in breast cancer immunopathogenesisCell Biology International, 2024
- Structural insights into rapamycin‐induced oligomerization of a FRB–FKBP fusion proteinFEBS Letters, 2024
- Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancerChemico-Biological Interactions, 2024
- Manganese induces neuronal apoptosis by activating mTOR signaling pathway in vitro and in vivoFood and Chemical Toxicology, 2024
- Nutrient-regulated control of lysosome function by signaling lipid conversionCell, 2023
- Proactively Reducing Anti‐Drug Antibodies via Immunomodulatory BioconjugationAngewandte Chemie International Edition, 2019
- A Kinase Inhibitor Targeted to mTORC1 Drives Regression in GlioblastomaCancer Cell, 2017
- Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12Biochemical Pharmacology, 2009
- Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expressionFEBS Letters, 1995